MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2023 International Congress

    Empowerment of People with Parkinson`s disease: development, testing and evaluation of a cross-sectoral, intervention-based self-management program

    T. Thomsen, S. Skovbølling, M. Møller, V. Grønlund, M. Brønden, B. Biering-Sørensen (Glostrup, Denmark)

    Objective: The overall purpose of this study is to develop, test and evaluate the results of a self-management program targeted PwP with the aim of…
  • 2023 International Congress

    Efficacy and safety of clonidine for the treatment of impulse control disorder in Parkinson’s disease: a multicentre, parallel, randomised, double blind, phase 2b clinical trial

    C. Laurencin, A. Marques, D. Dilly Duchez, C. Giordana, S. Meoni, M. Anheim, P. Boulinguez, B. Ballanger, S. Thobois (Lyon, France)

    Objective: We aimed to assess whether clonidine, a specific α2-adrenergic receptor agonist, would improve impulse controls disorders (ICDs). Background: ICDs are frequently encountered in Parkinson’s…
  • 2023 International Congress

    Baseline characteristics for patients with multiple system atrophy entering a randomized, controlled study of the anti-α-synuclein monoclonal antibody Lu AF82422

    W. Singer, A. Takeda, L. Kjærsgaard, J. Wiedemann, A. Berger, A. Varrone, A. Bidani, D. Meulien (Rochester, USA)

    Objective: Report baseline characteristics for patients with multiple system atrophy (MSA) entering a study to assess the safety and efficacy of alpha-synuclein (α-syn) monoclonal antibody…
  • 2023 International Congress

    Introducing the molecular subtyping of Progressive Supranuclear Palsy: a proof of concept

    I. Martinez-Valbuena, S. Lee, E. Santamaria, J. Fernandez-Irigoyen, B. Couto, N. Reyes, H. Tanaka, S. Forrest, A. Kim, H. Qamar, J. Li, A. Karakani, K. Senkevich, E. Rogaeva, N. Visanji, A. Lang, G. Kovacs (Toronto, Canada)

    Objective: To enhance understanding of the molecular mechanisms underlying disease heterogeneity in Progressive supranuclear palsy (PSP) Background: PSP is a 4R-tauopathy characterised by subcortical pathology…
  • 2023 International Congress

    Disease progression in multiple system atrophy: the value of clinical cohorts with long follow-up

    T. Saulnier, M. Fabbri, A. Pavy-Le Traon, M. Le Goff, C. Helmer, P. Péran, WG. Meissner, O. Rascol, C. Proust-Lima, A. Foubert-Samier (Bordeaux, France)

    Objective: To describe MSA progression according to the latent disease continuum and assess the value of long-term follow-up. Background: Although essential for therapeutic development, describing…
  • 2023 International Congress

    DYT1 gene mutation: an atypical presentation with myoclonic dystonia

    G. Belluscio, F. Valentino, G. Cosentino, S. Gana, R. Zangaglia, C. Pacchetti (Pavia, Italy)

    Objective: In the present work, we describe the case of a 54 years old man who presented a young-age onset (7-8 years old) of unilateral…
  • 2023 International Congress

    miRNAs from blood serum as an early diagnostic biomarker for Parkinson’s disease: A study in an animal model

    MD. Ahmad, PSD. Dholaniya (Hyderabad, India)

    Objective: This work aims to elucidate miRNA-based biomarkers for the early stages of Parkinson`s Disease diagnosis in a chemically induced PD rat model. Background: The…
  • 2023 International Congress

    Comparision of objective Parkinson’s disease monitoring systems and the interpretations of results

    G. Kilincalp, F. Grahn, H. Sabir, D. von Below, A. Jeppsson, A. Sjöström, F. Bergquist (Gothenburg, Sweden)

    Objective: To examine the agreeement between two objective Parkinson’s disease (PD) monitoring systems (PKG and STAT-ON) and clinical information from a resident physician’s interview or…
  • 2023 International Congress

    Detailed illustration of a Turkish patient with homozygous C19ORF12 mutation

    H. Onder, T. Comoglu, S. Comoglu (Ankara, Turkey)

    Objective: To illustrate a rare Turkish patient with homozygous C19ORF12 mutation and discuss limitations regarding the current terminology and classification. Background: Neurodegeneration with brain iron…
  • 2023 International Congress

    Adult onset cerebrotendinous xanthomatosis (CTX) with parkinsonism responding to bilateral subthalamic nucleus deep brain stimulation

    R. Tilney, N. Dingli, E. Said, L. Zrinzo, J. Aquilina (London, United Kingdom)

    Objective: To describe a young male diagnosed with cerebrotendinous xanthomatosis who responded favourably to subthalamic nucleus deep brain stimulation (STN-DBS). Background: Cerebrotendinous Xanthomatosis is an…
  • « Previous Page
  • 1
  • …
  • 16
  • 17
  • 18
  • 19
  • 20
  • …
  • 186
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley